	US 12,202,871 B2
	Methods of treatment using G-CSF protein complex
Gajanan Bhat, Irvine, CA (US); and Shanta Chawla, Irvine, CA (US)
Assigned to Spectrum Pharmaceuticals, Inc., Irvine, CA (US)
Filed by Spectrum Pharmaceuticals, Inc., Irvine, CA (US)
Filed on Jan. 28, 2022, as Appl. No. 17/586,872.
Application 17/586,872 is a division of application No. 16/428,351, filed on May 31, 2019, granted, now 11,267,858.
Prior Publication US 2022/0153799 A1, May 19, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/535 (2006.01); A61K 47/68 (2017.01); A61K 38/00 (2006.01)

CPC C07K 14/535 (2013.01) [A61K 47/6811 (2017.08); A61K 38/00 (2013.01)]

20 Claims

1. A method for treating or preventing neutropenia in a patient receiving chemotherapy, comprising administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an N-terminus of an immunoglobulin Fc region via a non-peptidyl polymer, wherein the modified hG-CSF comprises the amino acid sequence of SEQ ID NO: 1.